<DOC>
	<DOC>NCT00516672</DOC>
	<brief_summary>This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.</brief_summary>
	<brief_title>Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criteria: Signed informed consent. Histologically or cytologically confirmed diagnosis of advanced solid tumor. Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study. ECOG performance status of 0 or 1. Adequate bone marrow reserve and hepatorenal function. Able to swallow and retain oral medication. For combo part, left ventricular ejection fraction within normal range or above 50%. Exclusion criteria: Prior treatment with pazopanib, and with lapatinib for combo part. Clinically significant gastrointestinal abnormalities. Sevier diseases or conditions other than cancer. Poorly controlled hypertension. Use of warfarin for therapeutic anticoagulation. Use of other antiangiogenesis agents, and other ErbB inhibitors for combo part. Unresolved and/or unstable toxicities Pregnant or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>lapatinib,</keyword>
	<keyword>cancer</keyword>
	<keyword>pharmacokinetics,</keyword>
	<keyword>safety,</keyword>
	<keyword>pazopanib,</keyword>
	<keyword>Japanese patients,</keyword>
</DOC>